Anti-L-selectin monoclonal antibody - AbgenixAlternative Names: DREG 200 - Abgenix
Latest Information Update: 25 Jul 2000
At a glance
- Originator Abgenix
- Mechanism of Action L-selectin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 25 Jul 2000 Discontinued-Preclinical for Inflammation in USA (Unknown route)
- 06 May 1997 Preclinical development for Inflammation in USA (Unknown route)